TAO Synergies TAOX
NASDAQ TAOX
$4.14 +0.13 (+3.24%)
As of: Sep 9, 2026 · 11:58 AM EDT

TAO Synergies (TAOX) Capital Expenditures (2020 - 2025)

TAO Synergies' (TAOX) quarterly Capital Expenditures came in at $10.6 million in Q4 2025, down 19.09% quarter-over-quarter from $13.1 million in Q3 2025.

Analysis

TAO Synergies (TAOX) Capital Expenditures (2020 - 2025) Analysis & Trends

TAO Synergies (TAOX) has reported Capital Expenditures for 4 consecutive years, with $10.6 million the latest figure, recorded in Q4 2025.

  • For the quarter ending Q4 2025, Capital Expenditures changed N/A year-over-year to $10.6 million; the trailing twelve-month figure through Dec 2025 stood at $23.6 million (changed N/A YoY), and the FY2025 full-year result was $28.1 million, changed N/A from the prior year.
  • Capital Expenditures eased to $10.6 million in Q4 2025 per TAOX's latest filing, from $13.1 million in the prior quarter.
  • Across five years, Capital Expenditures topped out at $13.1 million in Q3 2025 and bottomed at $669.0 in Q2 2023.
  • Historically, Capital Expenditures has averaged $3.9 million across 3 years, with a median of $2192.5 in 2022.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Capital Expenditures (Qtr)
1 Amgen 211.88 Bn 197.89 Bn 7.24 Bn 513.00 Mn
2 Gilead Sciences 181.55 Bn 178.37 Bn 6.22 Bn 140.00 Mn
3 Vertex Pharmaceuticals 132.31 Bn 124.45 Bn 2.84 Bn 112.20 Mn
4 Regeneron Pharmaceuticals 82.51 Bn 74.52 Bn 3.93 Bn 240.20 Mn
5 Argenx Se 61.54 Bn 56.36 Bn 1.37 Bn -
6 Moderna 54.69 Bn 49.55 Bn 52.00 Mn 37.00 Mn
7 Alnylam Pharmaceuticals 34.07 Bn 30.76 Bn 992.69 Mn 34.68 Mn
8 Biogen 31.41 Bn 30.12 Bn 1.96 Bn 40.90 Mn
9 Roivant Sciences 30.10 Bn 30.10 Bn 1.16 Mn -1.87 Mn
10 TAO Synergies 30.93 Mn 30.93 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2025 10.57 Mn
Sep 30, 2025 13.07 Mn
Jun 30, 2023 669.00
Mar 31, 2023 2,038.00
Dec 31, 2022 2,139.00
Sep 30, 2022 2,246.00
Jun 30, 2020 2,814.00
Mar 31, 2020 2,599.00